Trial reportMolecular psychiatry2021
Effects of aspirin on the long-term management of depression in older people: a double-blind randomised placebo-controlled trial.
Trial report in Molecular psychiatry, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed, 2 syntheses or guidelines pooled it, 24 citations in OpenAlex.
- Anti-inflammatory interventions for the treatment and prevention of depression among older adults: a systematic review and meta-analysis.Translational psychiatry · 2025Pooled it
- Genome-wide association study implicates the role of TBXAS1 in the pathogenesis of depressive symptoms among the Korean population.Translational psychiatry · 2024Pooled it
- Diet quality and depressive symptoms in older adults, assessing the effect modification by genetic predisposition and low-grade inflammation: a target trial emulation.Molecular psychiatry · 2026Article
- Genetic perspectives on the comorbidity of anxiety and mood disorders with cardiovascular disease.Nature cardiovascular research · 2026Review
- An international, double-blind, randomized, placebo-controlled clinical trial of adjunctive trimetazidine to treat people with bipolar depression (the TIDE trial) protocol.BMC psychiatry · 2026Article
- Aspirin use and risk of depression: a cross-sectional study.Frontiers in pharmacology · 2026Article
- Childhood insulin resistance and neural stem cell dysfunction in psychiatric disorders: Role ofWorld journal of stem cells · 2025Review
- Immunopsychiatry of late life depression: role of ageing-related immune/inflammatory processes in the development and progression of depression.Acta neuropsychiatrica · 2025Review
- Metabolic complications of psychotropic medications in psychiatric disorders: Emerging role ofWorld journal of psychiatry · 2024Review
- Inflammation in Posttraumatic Stress Disorder: Dysregulation or Recalibration?Current neuropharmacology · 2024Article
- Brain FADE syndrome: the final common pathway of chronic inflammation in neurological disease.Frontiers in immunology · 2024Review
- The Mind Body Connection in Dermatologic Conditions: A Literature Review.Journal of cutaneous medicine and surgery · 2023Review
- Depression Following Acute Coronary Syndrome: A Review.Reviews in cardiovascular medicine · 2023Review
- Pathophysiological mechanisms of post-myocardial infarction depression: a narrative review.Frontiers in psychiatry · 2023Review
- Acetylsalicylic Acid and Mood Disorders: A Systematic Review.Pharmaceuticals (Basel, Switzerland) · 2022Review
- Associations of Cardiovascular Agents and Metformin with Depression Symptoms: A Cross-Sectional Analysis from the HUNT Study, Norway.Drugs - real world outcomes · 2022Article
- Inflammation and serotonin deficiency in major depressive disorder: molecular docking of antidepressant and anti-inflammatory drugs to tryptophan and indoleamine 2,3-dioxygenases.Bioscience reports · 2022Article
- Trajectories of depressive symptoms in older adults and associated health outcomes.Nature aging · 2022Article
- The Kynurenine Pathway in Traumatic Brain Injury: Implications for Psychiatric Outcomes.Biological psychiatry · 2022Review
- Exploring the therapeutic potential of omega-3 fatty acids in depression.Environmental science and pollution research international · 2021Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
17 authors at 8 institutions in 2 countries.
Funding
Abstract
Late-life depression is common and often inadequately managed using existing therapies. Depression is also associated with increased markers of inflammation, suggesting a potential role for anti-inflammatory agents. ASPREE-D is a sub-study of ASPREE, a large multi-centre, population-based, double-blind, placebo-controlled trial of aspirin vs placebo in older Australian and American adults (median follow-up: 4.7 years) of whom 1879 were depressed at baseline. Participants were given 100 mg daily dose of aspirin or placebo. Depressive symptoms were assessed annually using the validated, self-rated short version of the Center for Epidemiological Studies Depression scale. There was a significant increase in depressive scores (0.6; 95% CI 0.2 to 0.9; χ
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.